We use cookies to deliver our online services. Details of the cookies we use and instructions on how to disable them are set out in our Cookies Policy. By using this website you agree to our use of cookies. To close this message click close.

The impact of the UPC on life science companies

14 April 2015

Life science companies face unique patent issues, for example concerning interim relief, research and clinical trial exemptions and supplementary protection certificates. Bert Oosting, Andreas von Falck, Stanislas Roux-Vaillard, Stephen Bennett and Daniel Brook examine how these questions will be addressed in the proposed UPC.

Life science companies face unique patent issues, for example concerning interim relief, research and clinical trial exemptions and supplementary protection certificates. Bert Oosting, Andreas von Falck, Stanislas Roux-Vaillard, Stephen Bennett and Daniel Brook examine how these questions will be addressed in the proposed UPC.

Click here to read the article.

 
Loading data